NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence
Ticker: NCEL · Form: 6-K · Filed: Jan 28, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: drug-development, preclinical, opioid-crisis, new-indication
TL;DR
NLS Pharma is testing Mazindol ER for fentanyl addiction. Big potential if it works.
AI Summary
On January 28, 2025, NLS Pharmaceutics Ltd. announced the initiation of a preclinical program for its drug Mazindol ER, aimed at treating fentanyl dependence. This marks a new therapeutic area for the company's development pipeline.
Why It Matters
This development could lead to a new treatment option for the opioid crisis, specifically targeting fentanyl addiction, a major public health concern.
Risk Assessment
Risk Level: medium — Preclinical programs are early-stage and have a high failure rate, but success could address a significant unmet medical need.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Mazindol ER (drug) — Investigational treatment
- January 28, 2025 (date) — Announcement date
- fentanyl dependence (medical_condition) — Target indication
FAQ
What is the primary purpose of the preclinical program announced by NLS Pharmaceutics?
The preclinical program is for Mazindol ER in the treatment of fentanyl dependence.
When was this announcement made by NLS Pharmaceutics?
The announcement was made on January 28, 2025.
What is the drug candidate being investigated?
The drug candidate is Mazindol ER.
What specific condition is Mazindol ER being investigated for?
Mazindol ER is being investigated for the treatment of fentanyl dependence.
Is this a new therapeutic area for NLS Pharmaceutics?
Yes, the filing indicates this is a new therapeutic area for the company's development pipeline.
Filing Stats: 278 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-01-28 08:00:31
Filing Documents
- ea0228867-6k_nlsphar.htm (6-K) — 10KB
- ea022886701ex99-1_nlsphar.htm (EX-99.1) — 31KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-25-007240.txt ( ) — 55KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: January 28, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2